

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/820,339	03/29/2001		Sara Fuchs	FUCHS=2A	3100
1444	7590	04/20/2006	EXAMINER		INER
BROWDY AND NEIMARK, P.L.L.C.				HAYES, ROBERT CLINTON	
624 NINTH STREET, NW SUITE 300			ART UNIT	PAPER NUMBER	
WASHINGTON, DC 20001-5303				1649	

DATE MAILED: 04/20/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
	·	09/820,339	FUCHS ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Robert C. Hayes, Ph.D.	1649				
Period fo	The MAILING DATE of this communication aported in the communication aported in the communication approximation	pears on the cover sheet with th	e correspondence address				
THE - Exte after - If the - If NO - Failt Any	MAILING DATE OF THIS COMMUNICATION.  Insions of time may be available under the provisions of 37 CFR 1.  SIX (6) MONTHS from the mailing date of this communication.  In period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period are to reply within the set or extended period for reply will, by statustive to reply within the set or extended period for reply will, by statustive to reply will, by statustive to reply will.  See 37 CFR 1.704(b).		days will be considered timely. om the mailing date of this communication. NED (35 U.S.C. § 133).				
Status							
1)🛛	Responsive to communication(s) filed on <u>06 F</u>	<del>-</del> ebruary 2006.	•				
2a) <u></u> ☐	This action is <b>FINAL</b> . 2b)⊠ Thi	s action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposit	ion of Claims						
5)⊠	Claim(s) <u>8,9,12,14-18,25,27,30,31 and 36-41</u> 4a) Of the above claim(s) is/are withdrawn Claim(s) <u>12</u> is/are allowed. Claim(s) <u>8,9,15-18,30,31 and 36-39</u> is/are rejucted to claim(s) <u>14,25,27,40 and 41</u> is/are objected to Claim(s) are subject to restriction and/or	n from consideration. ected. o.	n				
Applicat	ion Papers	·					
9)[	The specification is objected to by the Examin	er.					
10)	The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the	e drawing(s) be held in abeyance.	See 37 CFR 1.85(a).				
11)	Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the E		•				
Priority (	under 35 U.S.C. § 119						
12)⊠ a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of:  1. Certified copies of the priority document Certified copies of the priority document Copies of the certified copies of the priority document All Copies of the certified copies of the priority document Ceptical Copies of the certified copies of the priority document Copies of the certified copies of the priority document Copies of the certified copies of the priority document Copies of the certified copies of the priority document Copies of the certified copies of the priority document Copies of the Copies	nts have been received. Its have been received in Applicate the process of the pr	ation No ived in this National Stage				
Attachmen		_					
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔲 Interview Summa Paper No(s)/Mail					
3) 🔲 Infori	re of Draftsperson's Patent Drawing Review (P10-948)  mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08  r No(s)/Mail Date		Patent Application (PTO-152)				

Application/Control Number: 09/820,339 Page 2

Art Unit: 1649

## **DETAILED ACTION**

## Continued Examination Under 37 CFR 1.114

- 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/06/06 has been entered.
- 2. Applicants' arguments filed 2/06/05 have been considered but are not found persuasive.
- 3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 4. The objection to claims 25, 27, 28, 32, 36 & 40 because of misspelling "toleragen" is withdrawn due to the amendment or cancellation of the claims.
- 5. The rejection of claim 19 under 35 U.S.C. 112, second paragraph, as being indefinite is withdrawn due to the cancellation of this claim.

Application/Control Number: 09/820,339

Art Unit: 1649

- 6. The rejection of claims 8, 16-19, 30 & 36-39 under 35 U.S.C. 112, second paragraph, as being indefinite and incomplete is withdrawn due to the amendment or cancellation of the claims.
- 7. The rejection of claims 8, 9, 16-18, 30 & 36-39 under 35 U.S.C. 102(b) as being anticipated by Schoepfer et al. (1988), is withdrawn solely because of the "proviso" now recited in claim 8. Note that this rejection will likely be re-instated should Applicants obviate the new matter rejection below.
- 8. Claim 12 is allowed.
- 9. Claims 14, 25, 27 & 40-41 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

It is again suggested that claim 32 (iii) be amended to "a polypeptide H $\alpha$ 1-210 consisting of <u>the</u> amino acid residues of SEQ ID NO: 2" to reflect more conventional claim language.

10. Claims 8, 9, 15-18, 30-31 & 36-39 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled

Application/Control Number: 09/820,339

Art Unit: 1649

in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

No proper antecedent basis not conception in context with that described within the specification at the time of filing the instant application exists for the negative recitation of "with the proviso that said polypeptide tolerogen does not consist of residues 1-210 of SEQ ID NO: 2" after the functional language suggested by the Examiner related to  $\alpha$ -bungarotoxin. No such basis exists on page 28 of the specification; thereby, constituting new matter.

11. Claims 36-39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

It is ambiguous how a "polypeptide tolerogen [that] does not consist of residues 1-210 of SEQ ID NO: 2" can also "consist... of amino acid residues 1-210 of SEQ ID NO: 2" as recited in (c), which is contradictory.

12. Claims 8, 16-18, 30 & 36-39 stand rejected under 35 U.S.C. 102(b) as being anticipated by Talib et al. (1991; IDS Ref #AM), for the reasons made of record in Paper NOs: 11 (mailed 1/30/03), 14 (mailed 10/14/04), 20040721 & 20050603, and as follows.

In contrast to Applicants' arguments on pages 11-12 of the response, the recitation of "fused to an additional polypeptide at its N- and/or C-terminal end" to "amino acid residues 122-210 of SEQ ID NO: 2" in claims 8(iv) & 36 are still met by the teachings of Talib et al. (e.g., see page 291). *In arguendo*, the sole difference between Talib's sequence and DNA encoding Hα1-

Application/Control Number: 09/820,339 Page 5

Art Unit: 1649

210 of claims 8(iv), 30 & 36 is the mere addition/fusion of the Met start codon residue at the Nterminal end of SEO ID NO: 2, as indicated in Figure 1, which therefore, meets the "proviso that said tolerogen does not consist of residues 1-210 of SEQ ID NO: 2". In that this Met start codon is inherently removed during proteolytic processing of eukaryotic proteins, Talib's DNA then "cod[es] for a polypeptide tolerogen ... consisting of amino acid residues [1-210] of SEQ ID NO: 2". This fusion polypeptide of Talib also inherently "does not assume the native conformation of the a subunit of the human acetylcholine receptor" because Talib's polypeptide constitutes a truncated version of the human acetylcholine receptor which is the extracellular domain of this receptor subunit. Note, pages 20 & 26 of the specification disclose that the AChR α-subunit extracellular domain polypeptide itself functions as a tolerogen. Note further that it is well known in the art that polypeptides produced in *E.coli*, as taught by Talib, often are not properly folded, and therefore, do "not assume the native conformation of the  $\alpha$ -subunit of the human acetylcholine receptor", as recited. Nevertheless, in arguendo, because Talib teach a structure identical to that claimed, inherently it reasonably possesses any functional properties associated with that claimed structure. Thus, Applicants' arguments are not persuasive.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Robert Hayes whose telephone number is (571) 272-0885. The examiner can normally be reached on Monday through Thursday from 9:00 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on (571) 272-0867. The fax phone number for this Group is (571) 273-8300.

Art Unit: 1649

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Robert C. Hayes, Ph.D.

April 18, 2006

ROBERT C. HAYES, PH.D. PRIMARY EXAMINER